Qurient Co., Ltd. (115180.KQ)
- Previous Close
10,190.00 - Open
10,180.00 - Bid 10,010.00 x --
- Ask 10,080.00 x --
- Day's Range
9,960.00 - 10,210.00 - 52 Week Range
3,200.00 - 10,330.00 - Volume
139,351 - Avg. Volume
288,428 - Market Cap (intraday)
339.1B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.
www.qurient.com/Recent News: 115180.KQ
View MorePerformance Overview: 115180.KQ
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 115180.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 115180.KQ
View MoreValuation Measures
Market Cap
342.80B
Enterprise Value
296.44B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
34.79
Price/Book (mrq)
6.05
Enterprise Value/Revenue
32.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-256.73%
Return on Assets (ttm)
-29.09%
Return on Equity (ttm)
-44.43%
Revenue (ttm)
9.18B
Net Income Avi to Common (ttm)
-23.57B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
48.16B
Total Debt/Equity (mrq)
1.40%
Levered Free Cash Flow (ttm)
-14.23B